LCG
FATE icon

Lisanti Capital Growth’s Fate Therapeutics FATE Stock Holding History

Lisanti Capital Growth’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-125,350
Closed -$10.9M – 145
2021
Q2 		$10.9M Buy
125,350
+113,555
+963% +$9.15M 1.35% 18
2021
Q1 		$972K Buy
+11,795
New +$1.13M 0.12% 117
2020
Q2 		– Sell
-14,780
Closed -$328K – 127
2020
Q1 		$328K Buy
+14,780
New +$374K 0.11% 112
2019
Q4 		– Sell
-125,060
Closed -$1.94M – 117
2019
Q3 		$1.94M Buy
125,060
+63,445
+103% +$1.22M 0.63% 64
2019
Q2 		$1.25M Sell
61,615
-117,175
-66% -$2.11M 0.41% 78
2019
Q1 		$3.14M Buy
178,790
+36,030
+25% +$569K 1.11% 34
2018
Q4 		$1.83M Buy
+142,760
New +$1.99M 0.74% 56

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Lisanti Capital Growth's FATE Position: Q3 2021 in Review

Lisanti Capital Growth sold out of Fate Therapeutics (FATE) in Q3 2021, closing a stake of 125,350 shares — an estimated $10.9M sold.

Lisanti Capital Growth first reported a position in FATE in Q4 2018 and held it in 7 quarters. The position peaked at $10.9M in Q2 2021. 265 funds tracked by Wall St. Rank hold FATE as of Q3 2021.

  • Lisanti Capital Growth reported no remaining Fate Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Lisanti Capital Growth sold 125,350 Fate Therapeutics shares in Q3 2021, an estimated $10.9M.
  • Lisanti Capital Growth first reported a position in Fate Therapeutics in Q4 2018 and held it in 7 quarters.
  • Lisanti Capital Growth's Fate Therapeutics position peaked at $10.9M in Q2 2021.
  • 265 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2021.

Based on Lisanti Capital Growth's 13F filing for Q3 2021, filed 3 Nov 2021.